AU601708B2 - Creación de Inventos y Patentes con Inteligencia Artificial

AU601708B2 – Pseudoephedrine, brompheniramin therapy
– Google Patents

AU601708B2 – Pseudoephedrine, brompheniramin therapy
– Google Patents
Pseudoephedrine, brompheniramin therapy

Download PDF
Info

Publication number
AU601708B2

AU601708B2
AU67406/87A
AU6740687A
AU601708B2
AU 601708 B2
AU601708 B2
AU 601708B2
AU 67406/87 A
AU67406/87 A
AU 67406/87A
AU 6740687 A
AU6740687 A
AU 6740687A
AU 601708 B2
AU601708 B2
AU 601708B2
Authority
AU
Australia
Prior art keywords
dosage form
pseudoephedrine
brompheniramine
compartment
wall
Prior art date
1986-03-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
AU67406/87A
Other versions

AU6740687A
(en

Inventor
George V. Guittard
Larry Hamel
Felix A. Landrau
Patrick S.L. Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Alza Corp

Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1986-03-14
Filing date
1987-01-07
Publication date
1990-09-20

1987-01-07
Application filed by Alza Corp
filed
Critical
Alza Corp

1987-09-17
Publication of AU6740687A
publication
Critical
patent/AU6740687A/en

1990-09-20
Application granted
granted
Critical

1990-09-20
Publication of AU601708B2
publication
Critical
patent/AU601708B2/en

2007-01-07
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/13—Amines

A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K9/00—Medicinal preparations characterised by special physical form

A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy

A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides a dosage form (10) for delivering the beneficial drugs (17) pseudoephedrine and brompheniramine to an environment of use, the dosage form comprising:
a) a semi-permeable wall (12), permeable to the passage of fluid present in the environment of use but substantially impermeable to the passage of the drug, which wall surrounds and defines,
b) a compartment 16 containing a dosage amount of a beneficial agent (17) for delivery to the environment of use at a controlled rate, and
c) at least one passageway (14) in the wall (12) for connecting the interior of the compartment with the environment of use,
characterized by a lamina (13) comprising a beneficial drug disposed upon the exterior of the semi-permeable wall (12), said lamina being adapted for transfer of a beneficial agent to the environment of use for immediate therapeutic effect.

Description

COMMONWEALTH OF AUSTRA A 1 7 0 FORM PATENTS ACT 1952 CO0M PL ET E S PE C IF I CATIO0N FOR OFFICE USE: Application Number: Lodged: 6 7q((,fr7Class Int Cla Complete Specification Lodged: Accepted: Published: Priority: SRelated Art: This document contains the amendments made under bec;tton 49 and is correct forI printingJ a 9* 4 44 444 9 44 a a o~ Address of Applicant: Actual Inventor: ALZA CORPORATION 950 PA0r2 MILL. ROAD, PALO ALTO, CA 94303-0802
U.S.A.
LARRY HAMEL, FELIX A. L’JANDRAU, PATRICK S.-L WONG AND GEORGE V. GUITTARD Address for Service: SHELSTON WATERS, 55 Clarence Street, Sydney Complete Specification for the Invention entitled: !»PSEUDOEPHEDRINF, BROMPHENIRAMINE THERAPY» The following statement is a full description of this invention, including the best method of performing it known to me/us:- 1- 1 PSEUDOEPHEDRINE, BROMPHENIRAMINE 2
THERAPY
3 4 FIELD OF THE INVENTION 6 This invention pertains to both a beneficial composition 7 comprising the drug pseudoephedrine and brompheniramine, and to a 8 delivery system for administering the composition comprising the drugs 9 to a recipient.
4 BACKGROUND OF THE INVENTION 2 INVENTION o o a0 °14 Antihistamine and decongestants are used for the temporary relief of symptoms of the common cold, allergic rhinitis and sinusitis.
The antihistamine brompheniramine and the decongestant pseudoephedrine 17 are therapeutically indicated for recipients needing relief of these «’18 symptoms.
19 Brompheniramine is a propylamine derivative antihistamine.
Brompheniramine is a racemic mixture of the dextro and levo isomers.
21 Pharmacologic activity is predominantly due to the d-isomer.
22 Dextrobrompheniramine, the dextro isomer, is approximately twice as 23 active. Brompheniramine is administered for its effects as a 24 therapeutically acceptable salt, preferably as brompheniramine maleate. Brompheniramine maleate occurs as a white crystalline 26 powder, freely soluble in aqueous-type fluids, and it is absorbed from 27 the gastrointestinal tract.
28 Pseudoephedrine is sympathomimetic drug which occurs 1 a 1 naturally in plants of the Ephedra. Pseudoephedrine is a stereoisomer 2 of ephedrine. Pseudcephedrine is administered for its beneficial 3 effects as a therapeutically acceptable salt, preferably as the 4 hydrochloride or the sulfate. Pseudoephedrine hydrochloride occurs as a fine, white crystal or powder, it is very soluble in aqueous-type 6 fluids, and it is absorbed from the gastrointestinal tract.
7 It would be desirable to provide a pharmaceutical dosage 8 form comprising the two different drugs that are initially delivered 9 in a therapeutically effective amount, followed by delivery-of the drugs at a controlled rate, and for a time period, established to meet if a specific therapeutic need. That is, it would be desirable to pro- 4s4.
«»12 vide a dosage form that comprises an exterior lamina comprising ,3 pseudoephedrine and brompheniramine and a releasable binder, which «14 lamina delivers both drugs immediately for substantially eliminating the start-up time of the dosage form and for providing immediate 16 therapy to a recipient. The exterior drug-containing lamina for 17 delivering an initial drug-pulse acts in cooperation with the dosage 18 form that follows with the drugs then delivered at a controlled rate 19 over time.
Additionally, it would be desirable to provide a 21 pharmaceutical dosage form comprising the two different drugs for 22 their simultaneous administration for obtaining the physiological and 23 pharmacological benefits of each drug. Such a novel dosage form can 24 be used for the desired medical relief where each individual drug addresses different symptoms of the particular medical situation.
26 Prior to this invention, however, the coadministration of these drugs 27 in a predetermined ratio did not appear feasible. For example, 28 pseudoephedrine and brompheniramine appear kinetically incompatible in 1 a pharmaceutical osmotically-controlled dosage form for their respec- 2 tive administrations within prescribed ratios because of their individual 3 osmotic properties and their solubilities. Adjitionally, it is unobvious 4 from their pharmacokinetic properties that pseudoephedrine and brompheniramine can be coadministered from a dosage form to the body 6 at rates that are individually selected to achieve each of their 7 separate therapeutic plasma concentrations.
8 Thus, in the light of the above presentation, it will be 9 appreciated by those versed in the dispensing art, that if a’ novel and 0 unique dosage form is made available for first, administering a pulsed S1’~ amount of pseudoephedrine and brompheniramine and secondly, making «12 available a means for housing the pseudophedrine and brompheniramine 0 for their administration at a controlled and continuous rate in therapeutically effective ratios for obtaining the benefits of each drug, such a dosage form would have a definite use and be a valuable contri- ‘6 bution to the disoensing art.
S’17 OBJECTS OF THE INVENTION 18 Accordingly, it is an immediate object of this invention to 19 provide a composition comprising pseudoephedrine and brompheniramine that can be administered to biological receptor sites to produce the 21 desired pharmacokinetic effects.
S22 Another object of the invention is to provide a dosage form 23 that can dispense pseudoephedrine and brompheniramine in a preselected 24 ratio and at controlled rates for obtaining the pharmacological and the physiological benefit of each drug, and which dosage form thusly 26 represents an improvement and advancement in therapy.
27 Another object of the invention is to provide an osmotic 28 system manufactured in the form of an osmotic device that comprises an 3 I 1 exterior lamina composition comprising pseudoephedrine and 2 brompheniramine and a releasable binder that delivers the drugs 3 immediately for increasing the period of time oseudoephedrine and 4 brompheniramine are available for performing their beneficial effects, followed by prolonged release of the drugs from the interior of the 6 osmotic device.
7 Another object of the invention is to provide an osmotic 8 system adapted for administering pseudoephedrine and brompheniramine 9 to a warm-blooded animal from an lamina comprising pseudoephedrine and Jo0 i brompheniramine for delivering an initial pulse of these drugs which o «;E l acts in cooperation with the osmotic system that follows with delivery ’12 of pseudoephedrine and brompheniramine at a rate controlled by the 0 0 osmotic system.
14 Another object of the invention is to provide an osmoticallyoo 15 controlled dosage form that can house pseudoephedrine and brompheniramine 0 i o0 and can codispense the two drugs to their biological drug receptors 17 for their separate therapeutic activities over a prolonged period of time.
S18 Another object of the invention is to provide an osmotic 19 device comprising a single compartment containing a composition com- 20 prising a member selected from the group consisting of pseudoephedrine 21 and its therapeutically acceptable salts and brompheniramine and its 22 therapeutically acceptable salts, and which osmotic device can simul- 23 taneously administer the pseudoephedrine and the brompheniramine at a 24 preselected prescribed ratio for providing a complete pharmaceutical regimen for the two drugs to a warm-blooded animal.
26 Another object of the invention is to provide a complete 27 pharmaceutical regimen for a composition comprising a pseudoephedrine 28 and a brompheniramine with the pharmacological parameters of the 4 I r r i 1_ 1~ 1 composition more favorable than those of the drugs alone, and which 2 composition can be dispensed from an osmotic delivery system; the use 3 of which requires intervention only for initiation and possibly termi- 4 nation of the regimen.
Another object of the invention is to provide an osmotic 6 device for dispensing pseudoephedrine and brompheniramine, which osmotic 7 device comprises a wall member whose fluid permeability increases over 8 a prolonged period of time.
g Another object of the present invention is to provide an o»Tg osmotic therapeutic system comprising pseudoephedrine and brompheniramine o: o» that are codelivered at a mass ratio concomitantly with the system S12 exhibiting increased permeability that is gradual over time.
Pr 3 Other objects, features and advantages of the invention V4 will be more apparent to those versed in the art from the following specification, taken in conjunction with the drawings and the accompanying ‘1’6 claims.
1 7 BRIEF DESCRIPTION OF THE DRAWINGS 19 In the drawing figures, which are not drawn to scale, but are set forth to illustrate various embodiments of the invention, the 21 drawing figures are as follows: 22 Figure 1 is a view of an osmotic device designed and shaped 23 for orally administering the two beneficial drugs pseudoephedrine and 24 brompheniramine to the gastrointestinal tract; and, Figure 2 is an opened view of the osmotic device of 26 Figure 1 illustrating the ,.ructure of the osmotic device.
27 In the drawings and in the specification, like parts in 28 related figures are identified by like numbers. The terms appearing a, I I .1 -1 W M 1 earlier in the specification and in the description of the drawings, 2 as well as embodiments thernof, are further described elsewhere in th 3 disclosure.
4 DETAILED DESCRIPTION OF THE DRAWINGS 6 Turning now to the drawing figures in detail, which drawing 7 figures are an e,,:ample of the dosage form provided by the invention, 8 and which example is not to be considered as limiting, one example is 9 the osmotic dosage form illustrated in Figure 1 and 2 and d6signated y the numeral 10. In Figure 1, osmotic dosage form 10 comprises a body member 11 comprising a wall 12 illustrated in a continuous dashed 1.12 line, that surrounds and forms an internal compartment not seen in Figure 1. Device 10 further comprises an exterior lamina 13 and at 0 0 90 a 1’6 In Figure 2, osmotic dosage form 10 is seen in opened view 17 with wall 12 sectioned at 15. In Figure 2, osmotic dosage form 18 comprises body 11, wall 12 that surrounds and defines internal compar- 19 ment 16 and exterior lamina 13. Exterior lamina 13 is initially supported on at least a part, or all of the exterior surface of wall 21 12. Wall 12 comprises at least one exit means 14, or more than one 4 22 exit means 14 for dispensing the contents of compartment 16 from 23 dosage form 24 Wall 12 of dosage form 10 comprises a composition that is permeable to the passaqe of an exterior fluid present in the environ- 26 ment of use, and It is substantially impermeable to the passage of 27 druq 9 nd other ingredients present in compartment 16. Semi parmeabl e 28 wall 12 of device 10 is substantially inert, and it maintains its 1 physical and chemical integrity during the drug dispensing life of 2 dosage form 10. The phrase «keeps its physical and chemical integrity» 3 means wall 12 does not lose its structure and it does not change 4 during the dispensing life of dosage form 10. Wall 12 is formed of a composition comprising cellulose triacetate and hydroxypropyl cellulose.
6 Wall 12 comprises a composition containing from 70 to 85 weight percent 7 cellulose triacetate, and from 15 to 30 weight percent hydroxypropyl- 8 cellulose, with the total weight percent equal to 100. Wall 12, in 9 one presently preferred embodiment comprises 75 weight percent cellulose S0o triacetate and 25 weight percent hydroxypropylcellulose. In another u,1 preferred embodiment, wall 12 comprises 80 weight percent cellulose o, 12 triacetate and 20 weight percent hydroxypropylcellulose. The acetyl S 13 content of the cellulose triacetate can be from 39.8% to 43.5%. Wall 0 Q f 4 12 exhibits an increased permeability to the passage of fluid over time attributed to the presence of hydroxypropylcellulose in wall 12.
0 0 «1’6 This unique property of wall 12, acting in cooperation with dosage 17 form 10, enables dosage form 10 to deliver greater than 90% to 95% of 18 its drug content over a prolonged periid of 24 hours.
19 Dosage form 10, manufactured in the form of an osmotic device comprises a lamina 13 coated onto the exterior surface of wall 21 12. Lamina 13 comprises a composition 17, represented by dots, which 22 composition comprises the drugs pseudoephedrine and brompheniramine, 23 and an aqueous soluble carrier hydroxypropylmethylcellulose. Lamina 24 13 comprising composition 17 provides for making available instantly the drugs pseudoephedrine and brompheniramine, preferably as their 26 pharmaceutically acceptable salt. In operation, when device 10 is in 27 a fluid environment of use, lamia 13 dissolves or undergoes dissolu- 28 tion and concurrently delivers composition 17 to the drug receptors.
1 2 3 4 6 7 8 9 0 o o 2 ’12 o 14 15 e, 1!6 0 a 17 1b 19 21 22 23 24 26 27 28 Lamina 13 containing drug composit:in 17, by providing immediate drug delivery, essentially overcomes the time required for the drugs to be delivered from compartment 16 of device 10. A start-up time is needed for imbibing fluid through wall 12 for device 10 to hydrodynamically dispense the components of compartment 16 through exit passageway 14 to the environment of use. Lemina 13, in one presently preferred embodiment is formed of a composition comprising pseudoephedrine 55 to 65 mg, brompheniramine 5 to 8 mg and hydroxypropylmethylcellulose up to 100 mg. In another preferred embodiment lamina 13 comprises pseudoephedrine 25 to 35 mg, brompheniramine 2 to 5 mg and hydroxypropylmethylcellulose up to 100 mg. More specifically, lamina 13 in one embodiment comprises 60 mg of pseudoephedrine, 6 mg of brompheniramine and 34 mg of hydroxypropylmethylcellulose; in another embodiment 30 mg of pseudoephedrine, 3 mg of brompheniramine maleate and 67 mg of hydroxypropy lmethylcellulose; in another embodiment lamina 13 comprises 60 mg of pseudcephedrine, 6 mg of brompheniramine and 17 mg of hytdroxypropylmethylc8llulose; and in another embodiment mg of pseudoephedrine, 3 mg of bromphenrramine and 8 mg of hydroxypropylmethylcellulose. Lamina 13 begins to release the drug pair instantly in the fluid environment of Jse, and it completely releases all of the drug pair during the first thirty minutes. This instant release thereby provides the drug pair for immediate passage into the plasma of a recipient.
Internal compartment 16 houses a dispensable composition comprising the beneficial drugs pseudoephedrine 18, identified by dashes, and beneficial drug brompheniramine 19, identified by wavy lines. The two drugs are present in compartment 16 in a fixed ratio and they are dispensed at a rate of release essentially equal to the 1: 1 ratios at which drug 18 and drug 19 were formulated into compartment 2 16. The release rate ratio, essentially equal to their compartment 3 ratio, is both unobvious and unexpected based on thermodynamic phys;cs.
4 Thermodynamics indicates the two drugs would be released at their equilibrium solubility ratios, for example, in an embodiment comprising 6 pseudoephedrine hydrochloride and brompheniramine maleate at a ratio 7 of 1.75:1. While device 10 in operation codelivered pseudoephedrine 8 hydrochloride and brompheniramine maleate as their mass ratio of 15:1.
9 This release rate ratio is the same ratio the two drugs were formu- S lated into compartment 16. According to thermodynamic equilibrium i equations applicable to an osmotic dosage form for co-delivering i2 pseudoephedrine hydrochloride, identified as drug A, and bromphenira- S3» mine maleate, identified as drug B, the equations are as follows: «14 ST SA SB (1) wherein ST is the total solubility of drug A and drug B in fluid 16 imbibed into compartment 16; SA .s the solubility of drug A in the 17 fluid, and SB is the solubility of drug B in the fluid; the release 18 rate RRA for drug A is given by equation 19 RRA A SA (2) wherein SA is the solubility of drug A in fluid in the compartment, 21 2 k is the permeability of wall 12 to aqueous-type fluids present in the 22 S environment of use, h is the thickness of wall 12, Ai is the total 23 osmotic pressure gradient of the drug formulation across wall 12 24 against an exterior fluid present in the environment of use, and A is the area of wall 12; and by equation for the controlled release 26 rate RRB for drug Bias follows: 27 k RRB A AT SB (3) 28 9 1 wherein SB is the solubility of drug B in the presence of fluid 2 imbibed through wall 12 into compartment 16, k is the permeability of 3 wall 12 to the fluid present in the environment, h is the thickness of 4 wall 12, AiT is the total osmotic pressure gradient of the drug formulation across wall 12 against fluid present in the environment of 6 use, and A is the area of wall 12; then, combining equations and 7 the equilibrium soluDility ratio SR for drug A exemplified by 8 pseudoephedrine hydrochloride and for drug B exemplified by o brompheniramine maleate is given by equations and -RR S 572 mg/m R0 A A A 572 mg/ml 14) SRRB SB 327 mg/ml SR 1.75:1 12 ’13 Instead, the release rate ratios provided by this invention for drug A ’14 and drug B is given by equation as follows: A
C
A (6)
RR
B
C
B
16′ B 17 wherein CA is the concentration of drug A in compartment 16 at the ’18 initiation of the drug dispensing period, and CB is the concentration 19 of drug B at the beginning of the drug dispensing period, then RRA 120 A= 8 (7) 21 22 RRA 15:1 23 which two drugs, as determined by scientific ieasurements were co- 24 released in essentially the same ratio as their initial charge in compartment 16 at time zero. The ratio of the two drugs inside the 26 compartment can be selected according to their therapeutic :eed, I1 27 this preselection, the controlled release rate for the codelivered 28 drugs comprises essentially the same ratio as their mass ratio in the i 1 compartment. Generally, in one osmotic dosage form provided by the 2 invention the compartment contains from 170 to 200 mg of pseudoephedrine 3 and from 10 to 20 mg of brompheniramine, with more specific dosages 4 comprising 180 mg jf pseudoephedrine hydrochloride and 18 mg of brompheniramine maleate; and 180 mg of pseudoephedrine hydrochloride and 10 mg of brompheniramine maleate. In another osmotic dosage form 7 provided by the invention, the compartment contains from 80 to 110 mg 6 of pseudoephedrine and 3 to 8 mg of brompheniramine, with more specific 9 dosage forms comprising 90 mg of pseudoephedrine hydrochloride and 0 O 0 10. 5 mg of brompheniramine malEate; and 90 mg of pseudoephedrine o 11 hydrochloride and 3 mg of brompheniramine maleate. The preferred mass ;2 rntio is from 8:1 to 20:1 with a more specific mass ratio comprising 0 1 3′ 10:1 to 15:1 expressed as pseudoephedrine to brompheniramine. The 14 compartment can contain also from 20 to 30 mg of sodium chloride, usually about 25 mg in a dosage form. The sodium chloride aids in 06 codispensing a higher percent of the drugs delivered at zero-order, 17 usually 15 hours and longer. The compartment can contain also 18 hydroxypropylmethylcellulose as an aid for controlling the dissolution 19 of the composition in the oompartment.
The expression «exit means» as used herein comprises means 21 and methods suitable for coreleasing the beneficial drugs pseudoephedrine S 22 and brompheniramine from the dispensing device. The means include at 23 least one passageway or orifice that passes through wall 12 for commu- 24 nicating with the drugs in compartment 16, The expression «at least o;ie passageway» includes aperttre, orifice, bore, pore, porous ne:.t, 26 through which drugs can migrate, a hollow fiber, capillary ‘-ubr: 27 the like. The expression includes also a material 28 leached from well 12 in the fluid environment of u it A A 1 2 3 4 7 8 a o OO0 0 0 I0 14 ,1 1 7 8 21 22 23 24 26 27 28 least one passageway in the device, Representative materials suitable fur forming at least one passageway, or a multiplicity of passageways, include an erodible poly(glycolic) or poly(lactic) acid member in the wall, a gelatinous filament, poly(vinyl alcohol), leachable materials such as fluid removable pore forming polysaccharides, salts, or oxides, and the like. A passageway or a plurality of passageways can be formed by leaching a material such as sorbitol from the wall. The passageway can have any shape, such as round, triangular, square, elliptical, irregular and the like. The device can be constructed with one or more passageways in spacek apart relation on more than a single surface of a dosage form. Passageways, and equipment for forming passageways are disclosed in U.S. Pat. Nos. 3,916,899; 4,063,064 and 4,088,864 Passageways formed by leaching are disclosed in U.S. Pat. No. 4,200,098.
The osmotic dosage form of the invention is manufactured by standard manufacturing techniques. For example, the compartment forming ingredients are formulated by the wet granulation technique using an organic cosolvent, such as isopropyl alcohol methylene dichloride, 80/20 v/v (volume/volume) as the granulating fluid. The ingredients forming the compartment in one manufacture comprising pseudoephedrine hydrochloride, brompheniramlne maleate, sodium chloride, hydroxypropylmethy cellulose, and microcrystalline cellulose, are individually passed through a 40 mesh screen and then thoroughly blended in a mixer. Next, poly ~v(nylpyrrolldone) is dissolved in a portion of the granulation fluid, the cosolvent described immediately above. Then, the poly(vinylpyrrolodine solution) is slowly added to the dry powder blend with continual mixing in the blender. The granulating fluid is added until a wet blend is achieved, generally about It 1 1 S 2 3 4 6 7 8 a olO, 0 0 o «12 o 14 ’16 17 18 19 21 22 23 24 26 27 28 400 cc of granulating fluid per kilogram of blend. The wet mass blend is then forced through a 20 mesh screen onto oven trays and dried for 18 to 24 hours at 50 0 C. The dried granules are then sized with a mesh screen. Next, magnesium stearate and silicon dioxide are added to the dry, screened granular blend, and this blend passed through an 80 mesh screen. The granulation is then put into milling jars and mixed on a jar mill for 10 to 15 minutes.
In another process, the drugs pseudoephedrine and brompheniramine and other ingredients are blended in a fluid bed granulation. After the powders are dry blended, a granulation fluid comprising a solution of poly(vinyl pyrrolidone) in water, is sprayed onto the powders and dried in the granulator. This process granulateall of the ingredients together while adding the granulation solution.
After the granules are dried, the lubricant magnesium stearate is added to the granulation.
The composition forming blend, in either of the above processes, is then tabletted using a 4-station Manesty® tablet press.
The speed of the press is set at 30 rpm and the maximum load set at 2 tons. Two dosage forms are tabletted using the press, one using a 9/32 inch (7.15 mm) round, standard concave punch, and the other using a 3/8 inch (7.15 mm) round, standard concave punch.
The wall of the osmotic dosage systems, and the exterior instant release lanina can be formed by one technique using the air suspension procedure. This procedure consists in suspending and tumbling the drug forming compartment in a current of air and a wail forming, or lamina forming composition until, in either operation the wall or the lamina is applied to the drug forming compartment. The air suspension procedure is well-suited for independently forming the I b’ i i i. J~ ~14 1 wall or the lamind. The air suspension procedure is described in U.S.
2 Pat. Ro. 2,799,241; in J. Am. Pharm. Assoc. Vol. 48, pages 451 to 459, 3 1959; and ibid. Vol. 49, pages 82 to 84, 1960. Osmotic dosage-forming 4 system can also be coated with the wall forming composition with a Wurster® air suspension coater, using a methylene dichloride/methanol 6 cosolvent 80/20 V/V; using 2.5 to 4% solids. The Aeromatic® air 7 suspension coater using a methylene dichloride/methanol cosolvent 8 87/13 V/V also can be used for applying the wall or the lamina. Other S9o wall and laminating techniques such as pan coating can be used for C0 0O providing the dosage form. In the pan coating system, wall forming, o ,1 or lamina forming compositions are deposited by successive spraying of i 12 the compositions on the drugs accompanied by tumbling in a rotating o o Span. A pan coater is used to produce a thicker wall or lamina. A 14 larger volume of methanol can be used in a cosolvent to produce a 0″o15 thinrner wall or lamina. Finally, the wall or lamina coated comparto ‘1 ments are dried in a forced air oven at 50°C for a week to free the 17 dosage form of solvent. Generally, the wall formed by these techni- 18 ques will have a thickness of 2 to 20 mils with a presently preferred 19 thickness of 4 to 10 mils. The exterior lamina generally will have a thickness of 0.5 to 15 mils, usually 0.5 to 7.5 mils.
S 21 Exemplary solvent suitable for manufacturing the wall or S 22 the lamina include inert inorganic and organic solvents that do not 23 adversely harm the wall, the lamina, and the final systems. The 24 sol ents broadly include members selected from the group consisting of alcohols, ketones, esters, ethers, liphatic hydrocarbons, halogenated 26 solvents, cycloaliphatic solvents, aromatic, heterocyclic, aqueous, 27 and mixtures thereof.
28 Following the procedures of the invention a series of 14 1 dosage forms were prepared for dispensing pseudoephedrine and 2 brompheniramine. Representative dosage forms contained a total of 3 240 mg of pseudoephedrine and 24 my of brompheniramine with the drug 4 distribution in the dosage form comprising 180 mg of pseudoephedrine and 18 mg of brompheniramine in the compartment and 60 mg of 6 pseudoephedrine and 6 mg of brompheniramine in the lamina; a total 7 of 240 mg of pseudoephedrine and 16 mg of brompheniramine distributed 8 as 180 mg of pseudoephedrine and 10 mg of brompheniramine in the S9, compartment, and 60 mg of pseudoephedrine and 6 mg of brompheniramine 0 0 old, in the lamina; and 90 mg of pseudoephedrine and 5 mg of <11o brompheniramine in the compartment, and 30 mg of pseudoephedrine and °12 3 mg of brompheniramine in the lamina. o 000 o ~1 A representative example of a 240/16 dosage system, 14 expressed in weight percent is as follows: a compartment weighing 260 mg comprising 69% pseudoephedrine hydrochloride, 3.8% brompheniramine *1 I maleate, 9.6% sodium chloride, 3% hydroxypropylmethylcellulose, 17 microcrystalline cellulose, 3% polyvinyl pyrrolidone, 1% magnesium 18 stearate, and 0.5% silicon dioxide; a wall weighing 36.8 mg comprising 19 75% cellulose triacetate and 25 hydroxypropylcellulose; and, a lamina weighing 84.5% comprising 72.7% pseudoephedrine hydrochloride, 21 7.3% brompheniramine maleate, and 20% hydroxypropylnethylcellulose. 22 The dosage form can comprise an additional outermost coat of hydroxy- 23 propylmechylcellulose to enhance its taste and to improve its appearance. 24 The dosage form had four 0.5 mm passageways, and delivered its compartment pseudoephedrine hydrochloride in solution at approximately 26 10 mg/hr, and the brompheniramine maleate delivered in solution at the 27 contracted rate of approximately 0.6 mg/hr. 28 Another representative example containing a total of 120 mg 1 of pseudoephedrine and 8 mg brompheniramine of comprised the following: 2 a compartment weighing 130 mg consisting essentially of 69.1% pseudo- 3 ephedrine hydrochloride, 3.8% brompheniramine maleate, 9.6% sodium 4 chloride, 3% hydroxypropylmethylcellulose, 10% microcrystalline cellulose, 3% polyvinyl pyrrolidone, 1% magnesium stearate, and 0.5% silicon 6 dioxide; a wall weighing 21 mg comprising 75% cellulose triacetate and 7 25% hydroxypropylcellulose; and a lamina weighing 41.6 mg comprising 8 72.7% psemdoephedrine hydrochloride, 7.3% brompheniramine maleate and 9, 20% hydroxypropylcellulose. The dosage form had two 0.5 mm'passage- O1 ways and dispensed the pseudoephedrine hydrochloride thorough the passageways in solution at a rate of about 5 mg/hr and dispensed the SJ2 brompheniramine maleate in solution through the passageways at a rate S of 0.3 mg/hr. 14 Plasma profiles determined by a computer simulated study using pharmacokinetic data and release rates from dosage forms of the ,'16 invention indicated a dosage form index of 2.3 for pseudoephedrine and 17 1.7 for brompheniramine. 18 'n summary, it will be appreciated that the present inven- 19 tion contributes to the art an unobvious dosage form that possesses practical utility. While the invention has been described and pointed 21 out in detail with reference to operative embodiments thereof, it will S. 22 be understood that those skilled in the art will appreciate that 23 various changes, modifications, substitutions and omissions can be 24 made without departing from the spirit of the invention. It is intended, therefore, that the invention embraces those equivalents within the 26 scope of the claims which follow. 27 28 i i Claims (10) 1. A dosage form for delivering the beneficial drugs pseudoephedrine and brompheniramine to an environment of I use, the dosage form comprising: a) a wall comprising 70 to 85 weight percent cellulose triacetate and 15 to 30 weight percent hydroxypropylcellulose, which wall is permeable to the passage of fluid present in the environment, substantially 0 00 0 c S""impermeable to the passage of d'rug, and surrounds and defines; b) a compartment; 0 0 o oa o c) a dosage amount of pseudoephedrine and brompheniramine in the compartment; d) at least one passageway in the wall for 0 o connecting the compartment with the exterior of the dosage form; e) a iamina comprising pseudoephedrine, .o I 0 0 0 brompheniramine and hydroxypropylmethylcellulose in laminar arrangement with the exterior of the wall; and, o t u Sf) wherein when the dosage form is in operation, 00 the dosage form codelivers pseudoephedrine and brompheniramine at a ratio greater than their mutual equilibrium solubility in fluid that enters the dosage form. 2. A dosage form for delivering the beneficial drugs pseudoephedrine and brompheniramine to an environment of use, the dosage form comprising: I" 17 1 T a) a wall comprising 70 to 85 weight percent cellulose triacetate and 15 to 30 weight percent hydroxypropylcellulose, which wall is permeable to the passage of fluid present in the environment of use, substantially impermeable to the passage of drug, and surrounds and defines: b) a compartment; c) a dosage amount of pseudoephedrine and Q O0 o 0 c o o brompheniramine in the compartment, said drugs present in o o a mass ratio of from 8:1 to 20:1; O0 o, d) at least one passageway in the wall for S00 0 000 o 0o connecting the compartment with the exterior of the dosage 0000 form; e) a lamina comprising pseudoephedrine, oooo brompheniramine and hydroxypropylmethylcellulose in 000oo 0">o laminar arrangement with the exterior of the wall; and, o 0 0 f) wherein when the dosage form is in operation, OO 0 0o 0 the dosage form codelivers pseudoephedrine and brompheniramine in a mass ratio of from 8:1 to 20:1 to the D0 0 o o environment of use. 00 0 S° 3. The dosage form for delivering the beneficial drugs to the environment of use according to claim 2, wherein pseudoephedrine is present as its pharmaceutically acceptable salt.

4. The dosage form for delivering the beneficial drugs to the environment of use according to claim 2, wherein brompheniramine is present as its pharmaceutically acceptable salt. 18 y I vf. Hi-ii- ‘t 1 00 0 0000 0000 0 o 0 0 0 o 1 0 0 0o o 0 00 o o0 ooo o A dosage form for delivering the beneficial drugs pseudoephedrine and brompheniramine to a warm-blooded animal, wherein the dosage form comprises: a) a wall comprising 70 to 85 weight percent cellulose triacetate and 15 to 30 weight percent hydroxypropylcellulose, which wall is permeable to the passage of fluid present in the environment, substantially impermeable to the passage of drug, and surrounds and forms; b) a compartment; c) a dosage amount of 170 to 200 mg of pseudoephedrine and 10 to 20 mg of brompheniramine in the compartment; d) at least one passageway in the wall for connecting the compartment with the exterior of the dosage form; e) a lamina comprising 55 to 65 mg of pseudoephedrine, 5 to 8 mg of brompheniramine and hydroxypropylmethylcellulose in laminar arrangement with the exterior of the waLl; and, f) wherein when the dosage form is in operation, the dosage form codelivers from the compartment pseudoephedrine and brompheniramine in a mass ratio of 10:1 to 15:1 which ratio corresponds to their initial ratio in the compartment.

6. The dosage form for delivering the beneficial drugs according to claim 5, wherein the compartment comprises 180 mg of pseudoephedrine hydrochloride. A,) S19 _p ie c a I r 1.

7. The dosage form for delivering the beneficial drugs according to claim 5, wherein the compartment comprises mg of brompheniramine maleate.

8. The dosage form for delivering the beneficial drugs according to claim 5, wherein the lamina comprises 60 mg of pseudoephedrine hydrochloride.

9. The dosage form for delivering the beneficial drugs according to claim 5, wherein the lamina comprises 6 mg of o oo brompheniramine maleate. o 0 1oo A dosage form for delivering the beneficial drugs 0 on pseudoephedrine and brompheniramine to a warm-blooded o animal, wherein the dosage form comprises: a Ro o a) a wall comprising 70 to 85 weight percent cellulose triacetate and 15 to 30 weight percent oo hydroxypropylcellulose, which wall surrounds and defines; 0000 ooo b) a compartment; c) a dosage amount of 80 to 110 mg of o 00 0 0 0 c o pseudoephedrine and 3 to 8 mg of brompheniramine in the compartment; 00 00 0 d) at least one passageway in the wall for communicating the exterior of the dosage form with the compartment; A) a lamina comprising 25 to 35 mg of pseudoephedrine, 2 to 5 mg of brompheniramine and hydroxypropylmethylcellulose coated onto the exterior surface of the wall; and, f) wherein when the dosage form is in the animal, the dosage form codelivers from the compartment ‘1 Ju pseudoephedrine and brompheniramine in a mass ratio of 10:1 to 15:1 which corresponds to their initial ratio in the compartment.

11. The dosage form for delivering the beneficial dzugs according to claim 10, wherein the compartment comprises mg of pseudoephedrine hydrochloride.

12. The dosage form for delivering the beneficial drugs according to claim 10, wherein the compartment comprises 0 0 3 D mg of brompheniramine maleate. 000 S 13. The dosage form for delivering the beneficial drugs 0o according to claim 10, wherein the lamina comprises 30 mg a 0 o oo of pseudoephedrine hydrochloride. oo 0

14. The dosage form for delivering the beneficial drugs according to claim 10, wherein the lamina comprises 3 mg oo of brompheniramine maleate. o»‘o’o DATED this 23rd day of May, 1990 ALZA CORPORATION 0 0> 0 4 Attorney: IAN T. ERNST Fellow Institute of Patent Attorneys of Australia o of SHELSTON WATERS 0s l C’-2 A 1. A*’

AU67406/87A
1986-03-14
1987-01-07
Pseudoephedrine, brompheniramin therapy

Expired

AU601708B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US06/839,384

US4662880A
(en)

1986-03-14
1986-03-14
Pseudoephedrine, brompheniramine therapy

US839384

1986-03-14

Publications (2)

Publication Number
Publication Date

AU6740687A

AU6740687A
(en)

1987-09-17

AU601708B2
true

AU601708B2
(en)

1990-09-20

Family
ID=25279584
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU67406/87A
Expired

AU601708B2
(en)

1986-03-14
1987-01-07
Pseudoephedrine, brompheniramin therapy

Country Status (12)

Country
Link

US
(1)

US4662880A
(en)

EP
(1)

EP0237159B1
(en)

JP
(1)

JPH0725676B2
(en)

KR
(1)

KR870008583A
(en)

AT
(1)

ATE63059T1
(en)

AU
(1)

AU601708B2
(en)

CA
(1)

CA1255563A
(en)

DE
(1)

DE3769678D1
(en)

ES
(1)

ES2021028B3
(en)

GR
(1)

GR3001893T3
(en)

MX
(1)

MX9203556A
(en)

ZA
(1)

ZA87153B
(en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

DE3535536A1
(en)

1985-10-04
1987-04-09
Lentia Gmbh

METHOD FOR SIMULTANEOUS DRYING AND GRANULATING EXTRACT MATERIALS FROM DEFROSTED CALF BLOOD

US4801461A
(en)

1987-01-28
1989-01-31
Alza Corporation
Pseudoephedrine dosage form

US5023076A
(en)

1987-02-27
1991-06-11
Alza Corporation
Lamina comprising carboxyvinyl polymer

US4915952A
(en)

1987-02-27
1990-04-10
Alza Corporation
Composition comprising drug, HPC, HPMC and PEO

US4810502A
(en)

1987-02-27
1989-03-07
Alza Corporation
Pseudoephedrine brompheniramine therapy

DD295760A5
(en)

1989-01-31
1991-11-14
Martin-Luther-Universitaet Halle Wittenberg,De

DRUG DISTRIBUTION SYSTEM WITH COTROLLED ACTIVE INGREDIENT TRANSFER

US4948593A
(en)

1989-05-15
1990-08-14
Alza Corporation
Osmotic dosage form comprising an estrogen and a progestogen

US5045082A
(en)

1990-01-10
1991-09-03
Alza Corporation
Long-term delivery device including loading dose

US5204116A
(en)

1991-05-01
1993-04-20
Alza Corporation
Dosage form providing immediate therapy followed by prolonged therapy

DE4342091A1
(en)

1993-12-09
1995-06-14
Asta Medica Ag

Products for the application of initially high doses of Cetrorelix and manufacture of a combination pack for use in the treatment of diseases

DK1041990T3
(en)

1997-12-23
2006-10-02
Schering Corp

Composition for the treatment of respiratory and skin diseases with at least one leukotriene antagonist and at least one antihistamine

US6245357B1
(en)

1998-03-06
2001-06-12
Alza Corporation
Extended release dosage form

US8524277B2
(en)

1998-03-06
2013-09-03
Alza Corporation
Extended release dosage form

US6759062B2
(en)

2000-02-23
2004-07-06
Bioselect Innovations, Inc.
Composition and method for treating the effects of diseases and maladies

US6838093B2
(en)

2001-06-01
2005-01-04
Shire Laboratories, Inc.
System for osmotic delivery of pharmaceutically active agents

US20030185882A1
(en)

2001-11-06
2003-10-02
Vergez Juan A.
Pharmaceutical compositions containing oxybutynin

US8329217B2
(en)

2001-11-06
2012-12-11
Osmotica Kereskedelmi Es Szolgaltato Kft
Dual controlled release dosage form

JP4695326B2
(en)

2001-12-21
2011-06-08
第一三共ヘルスケア株式会社

Pharmaceutical composition for rhinitis

JP2009235093A
(en)

2001-12-21
2009-10-15
Daiichi Sankyo Healthcare Co Ltd
Pharmaceutical composition for nasal inflammation

US7442387B2
(en)

2003-03-06
2008-10-28
Astellas Pharma Inc.
Pharmaceutical composition for controlled release of active substances and manufacturing method thereof

US8691272B2
(en)

2005-12-30
2014-04-08
Intelgenx Corp.
Multilayer tablet

US20090169620A1
(en)

2007-12-21
2009-07-02
Venkatesh Gopi M
Orally disintegrating tablet compositions of temazepam

US20090246276A1
(en)

2008-01-28
2009-10-01
Graham Jackson
Pharmaceutical Compositions

US10610528B2
(en)

2009-12-08
2020-04-07
Intelgenx Corp.
Solid oral film dosage forms and methods for making same

US20110136815A1
(en)

2009-12-08
2011-06-09
Horst Zerbe
Solid oral film dosage forms and methods for making same

Citations (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4449983A
(en)

1982-03-22
1984-05-22

Alza Corporation

Simultaneous delivery of two drugs from unit delivery device

US4552899A
(en)

1984-04-09
1985-11-12

Analgesic Associates

Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4265874A
(en)

1980-04-25
1981-05-05
Alza Corporation
Method of delivering drug with aid of effervescent activity generated in environment of use

US4369172A
(en)

1981-12-18
1983-01-18
Forest Laboratories Inc.
Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose

US4457907A
(en)

1982-08-05
1984-07-03
Clear Lake Development Group
Composition and method for protecting a therapeutic drug

US4576604A
(en)

1983-03-04
1986-03-18
Alza Corporation
Osmotic system with instant drug availability

US4612008A
(en)

1983-05-11
1986-09-16
Alza Corporation
Osmotic device with dual thermodynamic activity

GB2150830B
(en)

1983-12-05
1987-08-19
Alza Corp
Drug dispenser

US4609374A
(en)

1985-04-22
1986-09-02
Alza Corporation
Osmotic device comprising means for governing initial time of agent release therefrom

1986

1986-03-14
US
US06/839,384
patent/US4662880A/en
not_active
Expired – Lifetime

1987

1987-01-06
KR
KR870000026A
patent/KR870008583A/en
not_active
Application Discontinuation

1987-01-07
AU
AU67406/87A
patent/AU601708B2/en
not_active
Expired

1987-01-09
ZA
ZA87153A
patent/ZA87153B/en
unknown

1987-01-27
EP
EP87300694A
patent/EP0237159B1/en
not_active
Expired – Lifetime

1987-01-27
DE
DE8787300694T
patent/DE3769678D1/en
not_active
Expired – Lifetime

1987-01-27
AT
AT87300694T
patent/ATE63059T1/en
not_active
IP Right Cessation

1987-01-27
ES
ES87300694T
patent/ES2021028B3/en
not_active
Expired – Lifetime

1987-02-04
CA
CA000528955A
patent/CA1255563A/en
not_active
Expired

1987-02-20
JP
JP62037697A
patent/JPH0725676B2/en
not_active
Expired – Fee Related

1991

1991-05-03
GR
GR91400302T
patent/GR3001893T3/en
unknown

1992

1992-06-26
MX
MX9203556A
patent/MX9203556A/en
unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4449983A
(en)

1982-03-22
1984-05-22
Alza Corporation
Simultaneous delivery of two drugs from unit delivery device

US4552899A
(en)

1984-04-09
1985-11-12
Analgesic Associates
Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs

US4552899B1
(en)

1984-04-09
1992-10-20
Analgesic Associates

Also Published As

Publication number
Publication date

ATE63059T1
(en)

1991-05-15

JPS62221625A
(en)

1987-09-29

MX9203556A
(en)

1992-09-01

CA1255563A
(en)

1989-06-13

ZA87153B
(en)

1987-09-30

EP0237159A3
(en)

1987-12-09

GR3001893T3
(en)

1992-11-23

DE3769678D1
(en)

1991-06-06

EP0237159A2
(en)

1987-09-16

KR870008583A
(en)

1987-10-19

ES2021028B3
(en)

1991-10-16

AU6740687A
(en)

1987-09-17

JPH0725676B2
(en)

1995-03-22

US4662880A
(en)

1987-05-05

EP0237159B1
(en)

1991-05-02

Información de contacto